Profile data is unavailable for this security.
About the company
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
- Revenue in USD (TTM)391.69k
- Net income in USD-52.34m
- Incorporated2014
- Employees40.00
- LocationOvid Therapeutics Inc441 NINTH AVENUE, 14TH FLOORNEW YORK 10001United StatesUSA
- Phone+1 (212) 776-4381
- Fax+1 (302) 636-5454
- Websitehttps://ovidrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 201.74m | 121.00 | -- | 1.18 | -- | 56.04 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 202.05m | 25.00 | -- | 2.42 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Codexis Inc | 70.14m | -76.24m | 204.58m | 174.00 | -- | 2.35 | -- | 2.92 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 205.50m | 75.00 | -- | 3.01 | -- | 22.97 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 206.90m | 42.00 | -- | 16.09 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -121.83m | 207.05m | 128.00 | -- | 0.8732 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 214.20m | -- | -- | 11.28 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Ovid Therapeutics Inc | 391.69k | -52.34m | 215.97m | 40.00 | -- | 2.46 | -- | 551.39 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 216.72m | 207.00 | -- | 4.40 | -- | 4.32 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.81m | 217.28m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 220.17m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 222.23m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Coherus Biosciences Inc | 257.24m | -237.89m | 222.46m | 306.00 | -- | -- | -- | 0.8648 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Renovaro Inc | 0.00 | -41.23m | 227.00m | 12.00 | -- | 2.46 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 229.33m | 49.00 | -- | 5.16 | -- | 2,831.27 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Data as of Apr 30 2024. Currency figures normalised to Ovid Therapeutics Inc's reporting currency: US Dollar USD
50.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 6.85m | 9.69% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 6.12m | 8.65% |
| Rubric Capital Management LPas of 31 Dec 2023 | 5.32m | 7.52% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.94m | 5.58% |
| Madison Avenue Partners LPas of 31 Dec 2023 | 3.65m | 5.16% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.94m | 4.16% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 2.50m | 3.54% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.66m | 2.34% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 1.48m | 2.09% |
| TLS Advisors LLCas of 31 Dec 2023 | 1.32m | 1.87% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
